C16 Biosciences snaps up $20m Series A

C16 Biosciences, a provider of sustainable alternatives to palm oil using biotechnology, has raised $20 million in Series A funding.

3 March 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles